FZ002-037 is a highly selective oral small-molecule SSTR4 agonist developed by Fermion. Preclinical studies indicate that the drug primarily provides peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management. It is the first domestically developed SSTR4 agonist in
Dr. Deco Deng, Founder of Fermion, stated: “We are delighted to partner with Simcere, a leading pharmaceutical company. As the first domestically developed and the world’s second high-selectivity SSTR4 agonist to enter the clinical stage, FZ002-037 holds great promise. By leveraging Simcere’s strong development and commercialization capabilities, we are confident in accelerating its progress to provide better treatment options for patients suffering from pain.”
Zhou Gaobo, Chief Investment Officer of Simcere, added: “Pain significantly affects patients’ quality of life and remains a major unmet clinical need. Addressing these ‘clinical pain points’ has always been a core mission for Simcere. We look forward to collaborating with innovative partners like Fermion to deliver more effective and safer pain therapies to patients as quickly as possible.”
Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in
About Fermion Technology
Fermion is a clinical-stage, AI-driven biotech company founded in 2019. The company focuses on developing differentiated best-in-class (BIC) and first-in-class (FIC) products in the central nervous system (CNS) and autoimmune fields. Leveraging its proprietary Drug Studio AI platform, Fermion prioritizes high target selectivity and tissue targeting to minimize off-target effects, ensure precise distribution in target tissues, and foster the development of innovative drugs with enhanced safety profiles.
For more information, please visit: www.fulmz.com. Â
About Simcere Pharmaceutical
Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D, and houses a “State Key Laboratory of Neurology and Oncology Drug Development”. Simcere is committed to “providing today’s patients with medicines of the future” across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, Simcere is also actively expanding presence in disease areas with significant clinical needs in the future.
Simcere’s industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and are seen as the partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in
For more information, please visit: www.simcere.com Â
About FZ002-037
FZ002-037 is a Phase II-ready non-opioid pain treatment that acts as an oral SSTR4 agonist. It is the first SSTR4 agonist to enter clinical trials in
For more information, please visit: https://www.fulmz.com Â
Investors and Media Contact: pr@fulmz.com Â